Acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer: Results of a pilot randomized trial
Restricted accessResearch articleFirst published online July, 2022
Acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer: Results of a pilot randomized trial
Fatigue often interferes with functioning in patients with advanced cancer, resulting in increased family caregiver burden. Acceptance and commitment therapy, a promising intervention for cancer-related suffering, has rarely been applied to dyads coping with advanced cancer.
Aim:
To examine the feasibility, acceptability, and preliminary efficacy of acceptance and commitment therapy for patient-caregiver dyads coping with advanced gastrointestinal cancer. Primary outcomes were patient fatigue interference and caregiver burden.
Design:
In this pilot trial, dyads were randomized to six weekly sessions of telephone-delivered acceptance and commitment therapy or education/support, an attention control. Outcomes were assessed at baseline and at 2 weeks and 3 months post-intervention.
Setting/participants:
Forty patients with stage III–IV gastrointestinal cancer and fatigue interference and family caregivers with burden or distress were recruited from two oncology clinics and randomized.
Results:
The eligibility screening rate (54%) and retention rate (81% at 2 weeks post-intervention) demonstrated feasibility. At 2 weeks post-intervention, acceptance and commitment therapy participants reported high intervention helpfulness (mean = 4.25/5.00). Group differences in outcomes were not statistically significant. However, when examining within-group change, acceptance and commitment therapy patients showed moderate decline in fatigue interference at both follow-ups, whereas education/support patients did not show improvement at either follow-up. Acceptance and commitment therapy caregivers showed medium decline in burden at 2 weeks that was not sustained at 3 months, whereas education/support caregivers showed little change in burden.
Conclusions:
Acceptance and commitment therapy showed strong feasibility, acceptability, and promise and warrants further testing.
SungHFerlayJSiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71:209–249.
2.
McFarlandDCBreitbartWS.Gastrointestinal cancers. In: BreitbartWSButowPNJacobsenPB, et al. (eds) Psycho-oncology. 4th ed.New York, NY: Oxford University Press, 2021, pp.189–195.
3.
ClarkKLLoscalzoMTraskPC, et al. Psychological distress in patients with pancreatic cancer–an understudied group. Psychooncology2010; 19:1313–1320.
4.
PetterssonGBerteröCUnossonM, et al. Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer. Support Care Cancer2014; 22:1171–1179.
5.
ButtZParikhNDBeaumontJL, et al. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of cancer therapy (NCCN-FACT) hepatobiliary-pancreatic symptom index (NFHSI). Cancer2012; 118:5997–6004.
6.
PearceAHaasMVineyR, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS One2017; 12:e0184360.
7.
VardyJDhillonHMPondGR, et al. Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol2014; 25:2404–2412.
8.
TantoyIYCooperBADhruvaA, et al. Changes in the occurrence, severity, and distress of symptoms in patients with gastrointestinal cancers receiving chemotherapy. J Pain Symptom Manage2018; 55:808–834.
9.
WallingAMWeeksJCKahnKL, et al. Symptom prevalence in lung and colorectal cancer patients. J Pain Symptom Manage2015; 49:192–202.
10.
NippRDEl-JawahriAMoranSM, et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer2017; 123:4720–4727.
11.
BreitbartWRosenfeldBTobiasK, et al. Depression, cytokines, and pancreatic cancer. Psychooncology2014; 23(3): 339–345.
12.
HussonOMolsFvan de Poll-FranseLV, et al. The course of fatigue and its correlates in colorectal cancer survivors: a prospective cohort study of the PROFILES registry. Support Care Cancer2015; 23:3361–3371.
13.
MotaDDPimentaCACaponeroR.Fatigue in colorectal cancer patients: prevalence and associated factors. Rev Lat Am Enfermagem2012; 20:495–503.
14.
EngebretsonAMatrisianLThompsonC.Pancreatic cancer: patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. Pancreatology2015; 15:701–707.
15.
JandaMNealeREKleinK, et al. Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Pancreatology2017; 17:321–327.
16.
ShafferKMJacobsJMNippRD, et al. Mental and physical health correlates among family caregivers of patients with newly-diagnosed incurable cancer: a hierarchical linear regression analysis. Support Care Cancer2017; 25:965–971.
17.
WadhwaDBurmanDSwamiN, et al. Quality of life and mental health in caregivers of outpatients with advanced cancer. Psychooncology2013; 22:403–410.
18.
HanlyPMaguireRHylandP, et al. Examining the role of subjective and objective burden in carer health-related quality of life: the case of colorectal cancer. Support Care Cancer2015; 23:1941–1949.
19.
van RynMSandersSKahnK, et al. Objective burden, resources, and other stressors among informal cancer caregivers: a hidden quality issue?Psychooncology2011; 20:44–52.
20.
MaguireRHanlyPHylandP, et al. Understanding burden in caregivers of colorectal cancer survivors: what role do patient and caregiver factors play?Eur J Cancer Care2018; 27:e12527.
21.
YabroffKRKimY.Time costs associated with informal caregiving for cancer survivors. Cancer2009; 115:4362–4373.
22.
MückeMCuhlsHPeuckmann-PostV, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev2015; 2015:CD006788.
23.
PoortHPetersMBleijenbergG, et al. Psychosocial interventions for fatigue during cancer treatment with palliative intent. Cochrane Database Syst Rev2017; 7:CD012030.
24.
NorthouseLLKatapodiMCSongL, et al. Interventions with family caregivers of cancer patients: meta-analysis of randomized trials. CA Cancer J Clin2010; 60:317–339.
25.
BadrHKrebsP.A systematic review and meta-analysis of psychosocial interventions for couples coping with cancer. Psychooncology2013; 22:1688–1704.
26.
O'TooleMSZachariaeRRennaME, et al. Cognitive behavioral therapies for informal caregivers of patients with cancer and cancer survivors: a systematic review and meta-analysis. Psychooncology2017; 26(4): 428–437.
27.
HayesSCStrosahlKDWilsonKG.Acceptance and commitment therapy, second edition: the process and practice of mindful change. New York, NY: Guilford Press, 2012.
28.
Hulbert-WilliamsNJStoreyLWilsonKG.Psychological interventions for patients with cancer: psychological flexibility and the potential utility of acceptance and commitment therapy. Eur J Cancer Care2015; 24(1): 15–27.
29.
LiHWongCLJinX, et al. Effects of acceptance and commitment therapy on health-related outcomes for patients with advanced cancer: a systematic review. Int J Nurs Stud2021; 115:103876.
30.
MosherCESecintiELiR, et al. Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial. Support Care Cancer2018; 26:1993–2004.
31.
RostADWilsonKBuchananE, et al. Improving psychological adjustment among late-stage ovarian cancer patients: examining the role of avoidance in treatment. Cogn Behav Pract2012; 19:508–517.
32.
FerosDLLaneLCiarrochiJ, et al. Acceptance and commitment therapy (ACT) for improving the lives of cancer patients: a preliminary study. Psychooncology2013; 22:459–464.
33.
Mohabbat-BaharSMaleki-RiziFAkbariME, et al. Effectiveness of group training based on acceptance and commitment therapy on anxiety and depression of women with breast cancer. Iran J Cancer Prev2015; 8:71–76.
34.
ArchJJFishbeinJNFerrisMC, et al. Acceptability, feasibility, and efficacy potential of a multimodal acceptance and commitment therapy intervention to address psychosocial and advance care planning needs among anxious and depressed adults with metastatic cancer. J Palliat Med2020; 23:1380–1385.
35.
MosherCESecintiEHirshAT, et al. Acceptance and commitment therapy for symptom interference in advanced lung cancer and caregiver distress: a pilot randomized trial. J Pain Symptom Manage2019; 58:632–644.
36.
BadrHSmithCBGoldsteinNE, et al. Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: results of a randomized pilot trial. Cancer2015; 121:150–158.
37.
MosherCESecintiEJohnsSA, et al. Examining the effect of peer helping in a coping skills intervention: a randomized controlled trial for advanced gastrointestinal cancer patients and their family caregivers. Qual Life Res2017; 27:515–528.
38.
MosherCESecintiEKroenkeK, et al. Acceptance and commitment therapy for fatigue interference in advanced gastrointestinal cancer and caregiver burden: protocol of a pilot randomized controlled trial. Pilot Feasibility Stud2021; 7:99.
39.
HannDMDennistonMMBakerF.Measurement of fatigue in cancer patients: further validation of the fatigue symptom inventory. Qual Life Res2000; 9:847–854.
40.
HannDMJacobsenPBAzzarelloLM, et al. Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Qual Life Res1998; 7:301–310.
41.
CallahanCMUnverzagtFWHuiSL, et al. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care2002; 40:771–781.
42.
BauerJCapraSFergusonM.Use of the scored patient-generated subjective global assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr2002; 56:779–785.
43.
HigginsonIJGaoWJacksonD, et al. Short-form Zarit caregiver burden interviews were valid in advanced conditions. J Clin Epidemiol2010; 63(5): 535–542.
44.
PilkonisPAChoiSWReiseSP, et al. Item banks for measuring emotional distress from the patient-reported outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment2011; 18:263–283.
45.
DongNMaynardR.PowerUp!: a tool for calculating minimum detectable effect sizes and minimum required sample sizes for experimental and quasi-experimental design studies. J Res Educ Eff2013; 6:24–67.
46.
SnowG. Blockrand: randomization for block random clinical trials (R package version 1.3). G. Snow and Intermountain Healthcare, 2013.
47.
Team RC. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2014.
48.
BédardMMolloyDWSquireL, et al. The Zarit Burden interview: a new short version and screening version. Gerontologist2001; 41:652–657.
49.
BuysseDJYuLMoulDE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep2010; 33:781–792.
50.
YuLBuysseDJGermainA, et al. Development of short forms from the PROMIS sleep disturbance and sleep-related impairment item banks. Behav Sleep Med2011; 10:6–24.
51.
HahnEADevellisRFBodeRK, et al. Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. Qual Life Res2010; 19:1035–1044.
52.
SmoutMDaviesMBurnsN, et al. Development of the valuing questionnaire (VQ). J Contextual Behav Sci2014; 3:164–172.
53.
BondFWHayesSCBaerRA, et al. Preliminary psychometric properties of the acceptance and action questionnaire-ii: a revised measure of psychological inflexibility and experiential avoidance undefined. Behav Ther2011; 42:676–688.
54.
CohenSRSawatzkyRRussellLB, et al. Measuring the quality of life of people at the end of life: the McGill quality of life questionnaire-revised. Palliat Med2017; 31:120–129.
55.
HaysRDBjornerJBRevickiDA, et al. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res2009; 18:873–880.
56.
KroenkeKBairMDamushT, et al. Stepped care for affective disorders and musculoskeletal pain (SCAMP) study: design and practical implications of an intervention for comorbid pain and depression. Gen Hosp Psychiatry2007; 29:506–517.
57.
KroenkeKTheobaldDNortonK, et al. The Indiana cancer pain and depression (INCPAD) trial: design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants. Gen Hosp Psychiatry2009; 31:240–253.
58.
Kadan-LottickNSVanderwerkerLCBlockSD, et al. Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer2005; 104:2872–2881.
59.
VanderwerkerLCLaffREKadan-LottickNS, et al. Psychiatric disorders and mental health service use among caregivers of advanced cancer patients. J Clin Oncol2005; 23:6899–6907.
60.
KroenkeKKrebsEWuJ, et al. Stepped care to optimize pain care effectiveness (SCOPE) trial study design and sample characteristics. Contemp Clin Trials2013; 34:270–281.
61.
KroenkeKEvansEWeitlaufS, et al. Comprehensive vs. assisted management of mood and pain symptoms (CAMMPS) trial: study design and sample characteristics. Contemp Clin Trials2018; 64:179–187.
62.
HayesSCLuomaJBBondFW, et al. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther2006; 44(1): 1–25.
63.
MosherCEWingerJGHannaN, et al. Randomized pilot trial of a telephone symptom management intervention for symptomatic lung cancer patients and their family caregivers. J Pain Symptom Manage2016; 52:469–482.
64.
PorterLSKeefeFJBaucomDH, et al. Partner-assisted emotional disclosure for patients with gastrointestinal cancer: results from a randomized controlled trial. Cancer2009; 115:4326–4338.
65.
JakobsenJCGluudCWetterslevJ, et al. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol2017; 17:162.
66.
AtkinsDC.Using multilevel models to analyze couple and family treatment data: basic and advanced issues. J Fam Psychol2005; 19:98–110.
67.
KennyDKashyDCookW.Dyadic data analysis. New York, NY: Guilford Press, 2006.
68.
RosenthalR.Parametric measures of effect sizes. In: CooperHHedgesLV (eds) The handbook of research synthesis. New York, NY: Russell Sage, 1994, pp.231–244.
69.
ShriderEAKollarMChenF, et al. Income and poverty in the United States: current population reports. Washington, D.C.: U.S. Census Bureau, 2020, pp.60–273.
70.
SongLQan’irYGuanT, et al. The challenges of enrollment and retention: a systematic review of psychosocial behavioral interventions for patients with cancer and their family caregivers. J Pain Symptom Manage2021; 62:e279–e304.
71.
ButtZRosenbloomSKAbernethyAP, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw2008; 6:448–455.
72.
GilliesKKearneyAKeenanC, et al. Strategies to improve retention in randomised trials. Cochrane Database Syst Rev2021; 3:MR000032.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
